$ZIOP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ZIOPHARM ONCOLOGY INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ZIOPHARM ONCOLOGY INC. Get notifications about new insider transactions in ZIOPHARM ONCOLOGY INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 14 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Payment of Exercise | F | 5.47 | 13,980 | 76,471 | 141,870 | 155.9 K to 141.9 K (-8.97 %) |
Jun 14 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Buy | M | 4.85 | 15,000 | 72,750 | 155,850 | 140.9 K to 155.9 K (+10.65 %) |
Jun 14 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Option Exercise | M | 4.85 | 15,000 | 72,750 | 0 | |
Jun 14 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Payment of Exercise | F | 5.47 | 13,300 | 72,751 | 205,370 | 218.7 K to 205.4 K (-6.08 %) |
Jun 14 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Buy | M | 4.85 | 15,000 | 72,750 | 218,670 | 203.7 K to 218.7 K (+7.36 %) |
Jun 05 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | COO, CLO, and Secre ... | Payment of Exercise | F | 6.11 | 16,666 | 101,829 | 173,551 | 190.2 K to 173.6 K (-8.76 %) |
Jun 01 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,104 | 0 | 111,598 | |
May 09 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Cooper Laurence James Neil | Chief Executive Off ... | Payment of Exercise | F | 7.12 | 132,000 | 939,840 | 1,077,291 | 1.2 M to 1.1 M (-10.92 %) |
May 02 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,094 | 0 | 110,494 | |
Mar 31 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,083 | 0 | 109,400 | |
Mar 02 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,072 | 0 | 108,317 | |
Feb 02 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,061 | 0 | 107,245 | |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | LEBEL FRANCOIS | Executive Vice Pres ... | Payment of Exercise | F | 5.35 | 21,667 | 115,918 | 137,683 | 159.4 K to 137.7 K (-13.60 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | LEBEL FRANCOIS | Executive Vice Pres ... | Grant | A | 0.00 | 94,350 | 0 | 159,350 | 65 K to 159.4 K (+145.15 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Payment of Exercise | F | 5.35 | 9,333 | 49,932 | 57,967 | 67.3 K to 58 K (-13.87 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Grant | A | 0.00 | 39,300 | 0 | 67,300 | 28 K to 67.3 K (+140.36 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Cooper Laurence James Neil | Chief Executive Off ... | Payment of Exercise | F | 5.35 | 17,292 | 92,512 | 1,209,291 | 1.2 M to 1.2 M (-1.41 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Cooper Laurence James Neil | Chief Executive Off ... | Grant | A | 0.00 | 212,250 | 0 | 1,226,583 | 1 M to 1.2 M (+20.93 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Payment of Exercise | F | 5.35 | 6,665 | 35,658 | 352,502 | 359.2 K to 352.5 K (-1.86 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.00 | 17,204 | 0 | 359,167 | 342 K to 359.2 K (+5.03 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Tarriff Scott | Director | Option Exercise | A | 5.35 | 25,000 | 133,750 | 25,000 | |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Payment of Exercise | F | 5.35 | 10,664 | 57,052 | 140,850 | 151.5 K to 140.9 K (-7.04 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Grant | A | 0.00 | 17,204 | 0 | 151,514 | 134.3 K to 151.5 K (+12.81 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | COO, CLO, and Secre ... | Payment of Exercise | F | 5.35 | 21,667 | 115,918 | 190,217 | 211.9 K to 190.2 K (-10.23 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | COO, CLO, and Secre ... | Grant | A | 0.00 | 94,350 | 0 | 211,884 | 117.5 K to 211.9 K (+80.27 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Payment of Exercise | F | 5.35 | 9,331 | 49,921 | 203,670 | 213 K to 203.7 K (-4.38 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Grant | A | 0.00 | 17,204 | 0 | 213,001 | 195.8 K to 213 K (+8.79 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Payment of Exercise | F | 5.35 | 10,558 | 56,485 | 53,114 | 63.7 K to 53.1 K (-16.58 %) |
Jan 04 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Grant | A | 0.00 | 17,204 | 0 | 63,672 | 46.5 K to 63.7 K (+37.02 %) |
Dec 30 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,051 | 0 | 106,184 | |
Dec 30 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 17,204 | 0 | 139,513 | 122.3 K to 139.5 K (+14.07 %) |
Dec 01 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,040 | 0 | 105,133 | |
Nov 29 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | M | 6.49 | 15,000 | 97,350 | 0 | |
Nov 29 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Payment of Exercise | F | 7.22 | 13,483 | 97,347 | 46,468 | 60 K to 46.5 K (-22.49 %) |
Nov 29 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Buy | M | 6.49 | 15,000 | 97,350 | 59,951 | 45 K to 60 K (+33.37 %) |
Nov 02 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,030 | 0 | 104,093 | |
Oct 04 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,020 | 0 | 103,063 | |
Sep 02 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,010 | 0 | 102,043 | |
Aug 02 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,033 | 0 | 101,033 | |
Jul 06 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | P | 0.00 | 100,000 | 0 | 100,000 | |
Jun 03 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | COO, CLO, and Secre ... | Payment of Exercise | F | 7.74 | 6,667 | 51,603 | 117,534 | 124.2 K to 117.5 K (-5.37 %) |
May 09 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Cooper Laurence James Neil | Chief Executive Off ... | Payment of Exercise | F | 6.86 | 116,667 | 800,336 | 1,014,333 | 1.1 M to 1 M (-10.32 %) |
Mar 14 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | M | 5.01 | 15,000 | 75,150 | 0 | |
Mar 14 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Payment of Exercise | F | 8.16 | 9,210 | 75,154 | 44,951 | 54.2 K to 45 K (-17.00 %) |
Mar 14 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Buy | M | 5.01 | 15,000 | 75,150 | 54,161 | 39.2 K to 54.2 K (+38.30 %) |
Apr 22 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Option Exercise | M | 5.01 | 15,000 | 75,150 | 0 | |
Apr 22 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Buy | M | 5.01 | 15,000 | 75,150 | 341,963 | 327 K to 342 K (+4.59 %) |
Apr 20 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Option Exercise | M | 5.01 | 15,000 | 75,150 | 0 | |
Apr 20 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Payment of Exercise | F | 8.88 | 10,751 | 95,469 | 195,797 | 206.5 K to 195.8 K (-5.21 %) |
Apr 20 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Buy | M | 5.01 | 15,000 | 75,150 | 206,548 | 191.5 K to 206.5 K (+7.83 %) |
Apr 14 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Option Exercise | M | 5.01 | 15,000 | 75,150 | 0 | |
Apr 14 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Payment of Exercise | F | 7.92 | 11,694 | 92,616 | 134,310 | 146 K to 134.3 K (-8.01 %) |
Apr 14 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Buy | M | 5.01 | 15,000 | 75,150 | 146,004 | 131 K to 146 K (+11.45 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Cooper Laurence James Neil | Chief Executive Off ... | Grant | A | 0.00 | 131,000 | 0 | 1,131,000 | 1000 K to 1.1 M (+13.10 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | LEBEL FRANCOIS | Executive Vice Pres ... | Grant | A | 0.00 | 65,000 | 0 | 65,000 | 0 to 65 K |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Tarriff Scott | Director | Option Exercise | A | 8.31 | 40,000 | 332,400 | 40,000 | |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.00 | 26,661 | 0 | 326,963 | 300.3 K to 327 K (+8.88 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Payment of Exercise | F | 8.31 | 4,177 | 34,711 | 300,302 | 304.5 K to 300.3 K (-1.37 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Payment of Exercise | F | 8.31 | 1,462 | 12,149 | 304,479 | 305.9 K to 304.5 K (-0.48 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | COO, CLO, and Secre ... | Grant | A | 0.00 | 65,000 | 0 | 124,201 | 59.2 K to 124.2 K (+109.80 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Grant | A | 0.00 | 28,000 | 0 | 28,000 | 0 to 28 K |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Grant | A | 0.00 | 26,661 | 0 | 39,161 | 12.5 K to 39.2 K (+213.29 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Grant | A | 0.00 | 26,661 | 0 | 131,004 | 104.3 K to 131 K (+25.55 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Payment of Exercise | F | 8.31 | 6,683 | 55,536 | 104,343 | 111 K to 104.3 K (-6.02 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Payment of Exercise | F | 8.31 | 2,340 | 19,445 | 111,026 | 113.4 K to 111 K (-2.06 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Grant | A | 0.00 | 26,661 | 0 | 191,548 | 164.9 K to 191.5 K (+16.17 %) |
Jan 05 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Payment of Exercise | F | 8.31 | 2,047 | 17,011 | 164,887 | 166.9 K to 164.9 K (-1.23 %) |
Jan 04 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 26,661 | 0 | 122,309 | 95.6 K to 122.3 K (+27.87 %) |
Nov 23 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | COO, CLO, and Secre ... | Option Exercise | M | 2.30 | 153,333 | 352,666 | 76,667 | |
Nov 23 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | COO, CLO, and Secre ... | Sell | S | 12.84 | 153,333 | 1,968,796 | 59,201 | 212.5 K to 59.2 K (-72.15 %) |
Nov 23 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | COO, CLO, and Secre ... | Buy | M | 2.30 | 153,333 | 352,666 | 212,534 | 59.2 K to 212.5 K (+259.00 %) |
Sep 29 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Tarriff Scott | Director | Grant | A | 0.00 | 4,186 | 0 | 4,186 | 0 to 4.2 K |
Jun 11 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | LEBEL FRANCOIS | Executive Vice Pres ... | Option Exercise | M | 4.34 | 50,000 | 217,000 | 100,000 | |
Jun 11 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | LEBEL FRANCOIS | Executive Vice Pres ... | Sell | S | 10.12 | 50,000 | 506,000 | 0 | 50 K to 0 (-100.00 %) |
Jun 11 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | LEBEL FRANCOIS | Executive Vice Pres ... | Buy | M | 4.34 | 50,000 | 217,000 | 50,000 | 0 to 50 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 86,556 | 0 | 86,556 | 0 to 86.6 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 173,111 | 0 | 173,111 | 0 to 173.1 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 58,746 | 0 | 58,746 | 0 to 58.7 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 176,238 | 0 | 176,238 | 0 to 176.2 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 352,477 | 0 | 352,477 | 0 to 352.5 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 111,339 | 0 | 111,339 | 0 to 111.3 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 222,680 | 0 | 222,680 | 0 to 222.7 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 395,791 | 0 | 395,791 | 0 to 395.8 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 889,513 | 0 | 889,513 | 0 to 889.5 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 1,013,146 | 0 | 2,359,608 | 1.3 M to 2.4 M (+75.25 %) |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 61,262 | 0 | 61,262 | 0 to 61.3 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 138,975 | 0 | 138,975 | 0 to 139 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 154,181 | 0 | 154,181 | 0 to 154.2 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 29,066 | 0 | 29,066 | 0 to 29.1 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 34,318 | 0 | 34,318 | 0 to 34.3 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 358,386 | 0 | 358,386 | 0 to 358.4 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 337,333 | 0 | 337,333 | 0 to 337.3 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 9,537 | 0 | 9,537 | 0 to 9.5 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 53,245 | 0 | 53,245 | 0 to 53.2 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 240 | 0 | 240 | 0 to 240 |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 40,954 | 0 | 40,954 | 0 to 41 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 23,504 | 0 | 23,504 | 0 to 23.5 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 23,349 | 0 | 23,349 | 0 to 23.3 K |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 3,479,006 | 0 | 3,479,006 | 0 to 3.5 M |
Jun 08 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Sell | J | 0.00 | 17,830,305 | 0 | 0 | 17.8 M to 0 (-100.00 %) |
Jun 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Option Exercise | M | 2.30 | 27,500 | 63,250 | 55,000 | |
Jun 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Option Exercise | M | 0.80 | 3,334 | 2,667 | 0 | |
Jun 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Sell | S | 9.70 | 27,500 | 266,750 | 0 | 27.5 K to 0 (-100.00 %) |
Jun 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Buy | M | 2.30 | 27,500 | 63,250 | 27,500 | 0 to 27.5 K |
Jun 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Sell | S | 9.70 | 3,334 | 32,340 | 0 | 3.3 K to 0 (-100.00 %) |
Jun 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Buy | M | 0.80 | 3,334 | 2,667 | 3,334 | 0 to 3.3 K |
Jun 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Sell | S | 9.60 | 26,666 | 255,994 | 0 | 26.7 K to 0 (-100.00 %) |
Jun 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Sell | S | 9.55 | 5,837 | 55,743 | 12,500 | 18.3 K to 12.5 K (-31.83 %) |
Jun 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Sell | S | 9.72 | 34,163 | 332,064 | 18,337 | 52.5 K to 18.3 K (-65.07 %) |
Jun 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | COO, CLO, and Secre ... | Grant | A | 0.00 | 50,000 | 0 | 59,201 | 9.2 K to 59.2 K (+543.42 %) |
May 07 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Cooper Laurence James Neil | Chief Executive Off ... | Grant | A | 0.00 | 1,000,000 | 0 | 1,000,000 | 0 to 1000 K |
Feb 24 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Payment of Exercise | F | 10.06 | 14,601 | 146,886 | 9,201 | 23.8 K to 9.2 K (-61.34 %) |
Feb 10 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 8.75 | 1,440,000 | 12,600,000 | 17,830,305 | 16.4 M to 17.8 M (+8.79 %) |
Jan 05 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 16,707 | 0 | 95,648 | 78.9 K to 95.6 K (+21.16 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Option Exercise | A | 5.07 | 25,000 | 126,750 | 25,000 | |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Payment of Exercise | F | 5.07 | 2,047 | 10,378 | 166,934 | 169 K to 166.9 K (-1.21 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Payment of Exercise | F | 5.03 | 2,051 | 10,317 | 168,981 | 171 K to 169 K (-1.20 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Payment of Exercise | F | 5.07 | 8,633 | 43,769 | 372,120 | 380.8 K to 372.1 K (-2.27 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Grant | A | 0.00 | 16,707 | 0 | 380,753 | 364 K to 380.8 K (+4.59 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Option Exercise | A | 5.07 | 350,000 | 1,774,500 | 350,000 | |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 5.03 | 34,261 | 172,333 | 744,145 | 778.4 K to 744.1 K (-4.40 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Option Exercise | A | 5.07 | 75,000 | 380,250 | 75,000 | |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Payment of Exercise | F | 5.03 | 4,690 | 23,591 | 26,666 | 31.4 K to 26.7 K (-14.96 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | A | 5.07 | 25,000 | 126,750 | 25,000 | |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Payment of Exercise | F | 5.07 | 9,866 | 50,021 | 113,366 | 123.2 K to 113.4 K (-8.01 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Grant | A | 0.00 | 16,707 | 0 | 123,232 | 106.5 K to 123.2 K (+15.68 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.00 | 16,707 | 0 | 301,124 | 284.4 K to 301.1 K (+5.87 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Payment of Exercise | F | 5.07 | 6,167 | 31,267 | 284,417 | 290.6 K to 284.4 K (-2.12 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Payment of Exercise | F | 5.03 | 1,465 | 7,369 | 290,584 | 292 K to 290.6 K (-0.50 %) |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Option Exercise | A | 5.07 | 175,000 | 887,250 | 175,000 | |
Jan 02 2015 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Payment of Exercise | F | 5.03 | 7,192 | 36,176 | 23,802 | 31 K to 23.8 K (-23.20 %) |
Dec 10 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | X | 3.93 | 30,583 | 120,191 | 0 | |
Dec 10 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Buy | X | 3.93 | 30,583 | 120,191 | 364,046 | 333.5 K to 364 K (+9.17 %) |
Sep 16 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | X | 2.04 | 50,000 | 102,000 | 0 | |
Sep 16 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Buy | X | 2.04 | 50,000 | 102,000 | 333,463 | 283.5 K to 333.5 K (+17.64 %) |
Sep 10 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | X | 2.04 | 40,298 | 82,208 | 0 | |
Sep 10 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Sell | J | 3.12 | 26,366 | 82,262 | 283,463 | 309.8 K to 283.5 K (-8.51 %) |
Sep 10 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Buy | X | 2.04 | 40,298 | 82,208 | 309,829 | 269.5 K to 309.8 K (+14.95 %) |
Feb 25 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Payment of Exercise | F | 4.40 | 14,600 | 64,240 | 30,994 | 45.6 K to 31 K (-32.02 %) |
Jan 06 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Option Exercise | M | 0.08 | 242,979 | 19,438 | 0 | |
Jan 06 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Option Exercise | M | 0.08 | 25,674 | 2,054 | 0 | |
Jan 06 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Buy | M | 0.08 | 242,979 | 19,438 | 778,406 | 535.4 K to 778.4 K (+45.38 %) |
Jan 06 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Buy | M | 0.08 | 25,674 | 2,054 | 535,427 | 509.8 K to 535.4 K (+5.04 %) |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Option Exercise | A | 4.34 | 25,000 | 108,500 | 25,000 | |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Payment of Exercise | F | 4.34 | 5,854 | 25,406 | 171,032 | 176.9 K to 171 K (-3.31 %) |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Grant | A | 0.00 | 18,818 | 0 | 271,578 | 252.8 K to 271.6 K (+7.45 %) |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Option Exercise | A | 4.34 | 300,000 | 1,302,000 | 300,000 | |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 4.34 | 15,023 | 65,200 | 509,753 | 524.8 K to 509.8 K (-2.86 %) |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Option Exercise | A | 4.34 | 35,000 | 151,900 | 35,000 | |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Payment of Exercise | F | 4.34 | 4,690 | 20,355 | 31,356 | 36 K to 31.4 K (-13.01 %) |